PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)

• J. Westin,
• J. M. Burke,
• A. E. Chapman,
• T. Kilavuz,
• C. Xu,
• Y. Shmuely,
• J. Radford

Affiliations

J. Westin

1 Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston

J. M. Burke

2 US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora

A. E. Chapman

3 Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia

T. Kilavuz

4 ADC Therapeutics America, Inc, Murray Hill, United States of America

C. Xu

4 ADC Therapeutics America, Inc, Murray Hill, United States of America

Y. Shmuely

4 ADC Therapeutics America, Inc, Murray Hill, United States of America

J. Radford

5 NIHR Clinical Research Facility, the Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom